Proteolysis-Targeting Chimeras (PROTACs) are bifunctional molecules that bring a target protein and an E3 ubiquitin ligase into proximity to append ubiquitin, thus directing target degradation. Although numerous PROTACs have entered clinical trials, their development remains challenging, and their large size can produce poor drug-like properties. To overcome these limitations, we have modified our Coferon platform to generate Combinatorial Ubiquitination REal-time PROteolysis (CURE-PROs). CURE-PROs are small molecule degraders designed to self-assemble through reversible bio-orthogonal linkers to form covalent heterodimers. By modifying known ligands for Cereblon, MDM2, VHL, and BRD with complementary phenylboronic acid and diol/catechol linkers, we have successfully created CURE-PROs that direct degradation of BRD4 both and . The combinatorial nature of our platform significantly reduces synthesis time and effort to identify the optimal linker length and E3 ligase partner to each target and is readily amenable to screening for new targets.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1021/acs.jmedchem.3c02097 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Structural basis for C-degron selectivity across KLHDCX family E3 ubiquitin ligases.
Nat Commun
November 2024
Department of Structural Biology, St. Jude Children's Research Hospital, Memphis, TN, USA.
Article Synopsis
- This study focuses on how E3 ligases interact with substrates through specific C-degron sequences, which are essential for the ubiquitin-proteasome system’s function in protein degradation.* -
- Researchers compared ubiquitylation activities of various substrates and used techniques like biochemistry and crystallography to uncover how different E3 ligases from the KLHDCX family recognize C-degrons.* -
- Findings indicate that while a common anchoring motif aids in binding, variations in structure and additional interactions influence which substrates can be recognized and degraded, highlighting the complexity of substrate specificity.*
Discovery of CRBN-Dependent WEE1 Molecular Glue Degraders from a Multicomponent Combinatorial Library.
J Am Chem Soc
November 2024
Department of Chemical and Systems Biology, ChEM-H, Stanford School of Medicine, Stanford University, Stanford, California 94305, United States.
Small molecules promoting protein-protein interactions produce a range of therapeutic outcomes. Molecular glue degraders exemplify this concept due to their compact drug-like structures and ability to engage targets without reliance on existing cognate ligands. While cereblon molecular glue degraders containing glutarimide scaffolds have been approved for treatment of multiple myeloma and acute myeloid leukemia, the design of new therapeutically relevant monovalent degraders remains challenging.
View Article and Find Full Text PDFAn RNA damage response network mediates the lethality of 5-FU in colorectal cancer.
Cell Rep Med
October 2024
Center for Precision Cancer Medicine, David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Department of Surgery, Beth Israel Medical Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA. Electronic address:
Article Synopsis
- 5-fluorouracil (5-FU) is an important cancer treatment that mostly works by blocking a specific enzyme, leading to DNA damage, but clinical trials show it doesn't work well with certain other drugs for colorectal cancer.
- Research indicates that 5-FU actually kills colorectal cancer cells by targeting RNA during the process of making ribosomes, rather than mainly causing DNA damage, which some cancer types are more sensitive to.
- Strategies that increase ribosome production may enhance the effectiveness of 5-FU, suggesting that combining treatments that focus on this aspect could improve outcomes in cancer therapy.
Super Enhanced Purification of Denatured-Refolded Ubiquitinated Proteins by ThUBD Revealed Ubiquitinome Dysfunction in Liver Fibrosis.
Mol Cell Proteomics
November 2024
State Key Laboratory of Medical Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences Beijing, Research Unit of Proteomics & Research and Development of New Drug of Chinese Academy of Medical Sciences, Institute of Lifeomics, Beijing, PR China; School of Basic Medical, Anhui Medical University, Heifei, Anhui, PR China; College of Chemistry and Materials Science, Hebei University, Baoding, Hebei, PR China. Electronic address:
Article Synopsis
- * The study introduces a new method called denatured-refolded ubiquitinated sample preparation (DRUSP) combined with a tandem hybrid ubiquitin-binding domain (UBD), resulting in nearly three times stronger ubiquitin signals and a 10-fold improvement in protein enrichment compared to standard methods.
- * DRUSP enhances the stability and reproducibility of ubiquitinomics, successfully applied to analyze early liver fibrosis in mice, providing valuable insights into liver disease research.
Chemical Tools for Probing the Ub/Ubl Conjugation Cascades.
Chembiochem
September 2024
Structural Biology Program, Sloan Kettering Institute, 1275 York Avenue, New York, New York, 10065, USA.
Article Synopsis
- - The text explains the process of ubiquitin (Ub) and ubiquitin-like proteins (Ubls) conjugation, which is vital for many cellular functions and involves specific enzymes known as E1, E2, and E3.
- - The E1 enzyme activates Ub/Ubl through a reaction that depends on ATP, creating a thioester linkage that then transfers to E2, which works with E3 to attach Ub/Ubl to target substrates.
- - The review discusses various chemical tools and methods used to study the complex steps of Ub/Ubl activation and conjugation, aiming to deepen understanding of their mechanisms and capture the fleeting intermediates involved in this process.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!